Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BCL11A Enhancer Gene Editing for Sickle Cell Disease
NCT07708350Phase 1Recruiting
- Start
- Aug 2026
- Primary completion
- Dec 2028
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of exagamglogene autotemcel in sickle cell disease (SCD). Primary endpoint: Primary engraftment at 42 days. Started Aug 2026; status: recruiting.
02
Drugs
exagamglogene autotemcel
03
Conditions
sickle cell disease (SCD)
Beyond the preview
Go deeper on NCT07708350.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07708350.